Please assess the completion status of the following clinical trial:

Trial Title: Comparing Clinical Outcomes Between Ketamine-midazolam and Morphine-midazolam for Continous Sedation in ICU Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>12years of age.~2. Anticipated need for sedation for \>24hours.~Exclusion Criteria:~1. Hypertensive crisis i.e. sustained SBP \>200mmHg/DBP\>110mmHg~2. Status epilepticus~3. Ischemic heart disease and severe LV dysfunction~4. Persistent tachyarrythmias~5. History of mental illness~6. Hypersensitivity to ketamine, morphine or midazolam.~7. Tetanus -due to the muscle rigidity that may be caused by ketamine. Reasons for exclusions 1 to 4; Ketamine stimulates the sympathetic nervous system causing transient increase in myocardial work and blood pressure and has psychoactive effects

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ketamine-midazolam (Type: EXPERIMENTAL): Continous intravenous sedation with a colorless drug mixture in 50ml syringe containing 900mg ketamine and 36mg midazolam.
- Morphine-Midazolam (Type: ACTIVE_COMPARATOR): Continous intravenous sedation with a colourless drug mixture in 50ml syringes containing 54mg morphine and 36mg midazolam.

Based on this trial design, predict the completion outcome and termination type (if applicable).